zilganersen
zilganersen: 2 clinical trials tracked.
zilganersen evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about zilganersen, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (2)
Zilganersen Expanded Access Program for Individuals With Alexander Disease
Expanded AccessIonis Pharmaceuticals, Inc.
A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease
Primary endpoint: Percent Change from Baseline in the 10-Meter Walk Test (10MWT)
InterventionalRandomizeddouble54 enrolledStarted 2021-06Completion 2034-0713 sites · Australia, Canada, Israel, Italy…Ionis Pharmaceuticals, Inc.